[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Tongren Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":606},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,38,0,25,[9,45,81,111,134,160,186,211,236,257,285,306,327,351,376,399,419,442,465,485,506,525,549,567,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100645148","phase-4-perfluorohexyloctane-eye-drops-vs-sodium-hyaluronate-for-video-display-terminal-associated-dry-eye-100645148",false,"NCT07679685","Perfluorohexyloctane Eye Drops vs. Sodium Hyaluronate for Video Display Terminal-Associated Dry Eye","A Prospective, Multicenter, Randomized Controlled Trial on the Efficacy and Safety of Perfluorohexyloctane Eye Drops Versus 0.1% Sodium Hyaluronate Eye Drops in the Treatment of Video Display Terminal-associated Dry Eye","Inclusion Criteria:\n\n1. Age 18-70 years (inclusive), male or female;\n2. Subject reports dry eye symptoms for at least 6 months;\n3. Diagnosis of mild to moderate dry eye according to the Chinese Dry Eye Expert Consensus (2020) criteria:\n\n   * Mild dry eye: fluorescein tear film break-up time (FBUT) ≥2 seconds, no significant ocular surface damage signs, corneal fluorescein staining score \\\u003C5;\n   * Moderate dry eye: FBUT ≥2 seconds AND corneal fluorescein staining dots \\\u003C30 or not exceeding 2 quadrants;\n4. Normal tear secretion: Schirmer I test ≥10 mm\u002F5 min;\n5. Daily electronic screen usage \\>6 hours;\n6. Electronic screen use for at least 5 days\u002Fweek, for more than 1 year;\n7. Understands and provides written informed consent.\n\nExclusion Criteria:\n\n1. Allergy or hypersensitivity to any component of the study drugs;\n2. Requires the use of artificial tears (other than study drug), secretagogues, ocular surface repair agents, anti-inflammatory\u002Fantibiotic eye drops, or other dry eye-related drugs (e.g., muscarinic receptor blockers for visual fatigue) during the study period;\n3. Presence of any of the following ocular or systemic conditions:\n\n   * Active ocular infection, ocular inflammation, or active ocular allergy;\n   * Conjunctivochalasis, nasolacrimal duct obstruction;\n   * Glaucoma or elevated intraocular pressure;\n   * Retinal disease or ocular tumor;\n   * Requirement to wear contact lenses during the study;\n   * Obstructive sleep apnea syndrome or sleep disorders;\n   * Planned or ongoing physical therapy (intense pulsed light, meibomian gland massage, warm compress, thermopulsation) within 2 weeks before enrollment through the end of study;\n4. Ocular surgery within 3 months prior to enrollment, incomplete recovery from previous ocular surgery, or planned ophthalmic surgery during the study period;\n5. Current smoker;\n6. Pregnant or breastfeeding women, or women planning to become pregnant during the study period;\n7. Uncontrolled systemic disease, or use of systemic medications (e.g., beta-blockers, benzodiazepines, corticosteroids, antihistamines, or other medications that may interfere with tear production);\n8. History of anxiety or depression;\n9. Any other condition that, in the judgment of the investigator, would make the subject unsuitable for participation.","ALL","18 Years","70 Years",{"count":21,"type":22},159,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of perfluorohexyloctane (PFHO) eye drops (Hengqin®, Chengdu Shengdi Pharmaceutical Co., Ltd.) compared with 0.1% sodium hyaluronate eye drops in patients with video display terminal (VDT)-associated dry eye.\n\nParticipants aged 18-70 years with mild to moderate dry eye (confirmed by Chinese Dry Eye Expert Consensus 2020 criteria) who use video display terminal for more than 6 hours\u002Fday and at least 5 days\u002Fweek for more than 1 year will be enrolled. A total of 159 subjects will be randomized in a 2:1 ratio to the experimental group (PFHO eye drops, n=106) or control group (0.1% sodium hyaluronate eye drops, n=53), both administered 1 drop\u002Feye, 4 times daily (3-5 hour intervals), bilaterally, for 8 weeks.\n\nThe primary endpoint is the change from baseline in fluorescein tear film break-up time (FBUT) at Week 8. Secondary endpoints include FBUT changes at Weeks 2 and 4, standard patient evaluation of eye dryness（SPEED） questionnaire score changes, total corneal fluorescein staining (tCFS), partial blink rate (PBR), non-invasive tear film break-up time (NIBUT), lipid layer thickness (LLT), meibomian gland secretion quality score, and This is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of perfluorohexyloctane (PFHO) eye drops (Hengqin®, Chengdu Shengdi Pharmaceutical Co., Ltd.) compared with 0.1% sodium hyaluronate eye drops (Hialid®) in patients with video display terminal (VDT)-associated dry eye.\n\nParticipants aged 18-70 years with mild to moderate dry eye (confirmed by Chinese Dry Eye Expert Consensus 2020 criteria) who use electronic screens for more than 6 hours\u002Fday and at least 5 days\u002Fweek for more than 1 year will be enrolled. A total of 159 subjects will be randomized in a 2:1 ratio to the experimental group (PFHO eye drops, n=106) or control group (0.1% sodium hyaluronate eye drops, n=53), both administered 1 drop\u002Feye, 4 times daily (3-5 hour intervals), bilaterally, for 8 weeks.\n\nThe primary endpoint is the change from baseline in fluorescein tear film break-up time (FBUT) at Week 8. Secondary endpoints include FBUT changes at Weeks 2 and 4, SPEED questionnaire score changes, total corneal fluorescein staining (tCFS), partial blink rate (PBR), non-invasive tear film break-up time (NIBUT), lipid layer thickness (LLT), meibomian gland secretion quality score, and meibography score at Weeks 2, 4, and 8.",[28],"Dry Eye",[30,31],"Dry eye","video display terminal","NOT_YET_RECRUITING","2026-06-29",{"date":35,"type":36},"2026-07-01","ACTUAL",{"date":38,"type":22},"2026-06-30",{"date":40,"type":22},"2027-04-30",{"name":42,"class":43},"Beijing Tongren Hospital","OTHER",9,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100637410","preoperative-stapokibart-for-endoscopic-sinus-surgery-in-chronic-rhinosinusitis-with-nasal-polyps-100637410","NCT07616609","Preoperative Stapokibart for Endoscopic Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps","A Randomized, Placebo-Controlled, Double-Blinded Trial of Preoperative Stapokibart With Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps","Inclusion Criteria:\n\n* Possess the ability to understand the nature of the study and voluntarily sign an informed consent form (ICF);\n* Age between 18 and 75 years old, with no limitation on gender;\n* Bilateral CRSwNP meeting the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Chronic Sinusitis (2024);\n* Persistent presence of the following symptoms for ≥12 weeks prior to the screening\u002Fintroduction period:\n* Nasal congestion;\n* Any other symptom such as decreased\u002Floss of smell or rhinorrhea;\n* At the screening\u002Fintroduction period and baseline, total NPS ≥ 4 points and NPS ≥ 2 points in each nasal cavity;\n* At the screening\u002Fintroduction period and baseline, the subject reports moderate to severe nasal congestion or decreased smell (NCS or LoS score of 2 or 3 points);\n* During the screening\u002Fintroduction period, the Lund-Mackay score on sinus CT is ≥12 points bilaterally and ≥6 points unilaterally;\n* Must meet any of the following criteria for type 2 inflammation: Eosinophil count \\>55\u002Fhigh-power field or eosinophil percentage \\>27% in nasal polyp tissue during the induction period; eosinophil percentage ≥3.75% in peripheral blood in patients with asthma; eosinophil percentage ≥6.9% in patients without asthma;\n* If the subject has asthma, the condition must be stable as assessed by the investigator or specialist. For subjects treated with a stable dose of inhaled corticosteroids for at least 4 weeks before screening, the treatment may be continued during the study period, and the daily dose of inhaled corticosteroids must be ≤1000 μg fluticasone propionate or an equivalent dose of other inhaled corticosteroids.\n\nExclusion Criteria:\n\n* Previous ESS surgery including but not limited to septoplasty, turbinate reduction, nasal polyp removal, and sinus surgery;\n* Contraindications to general anesthesia;\n* Contraindications to stapokibart therapy;\n* Previous use of any anti-IL-4Rα biologic;\n* The patient has conditions or comorbidities that may prevent them from being evaluated for the primary efficacy endpoint, such as acute rhinitis, nasal infection or upper respiratory tract infection within 2 weeks prior to the screening period, acute asthma exacerbation within 4 weeks, current drug-induced rhinitis, allergic fungal sinusitis (AFRS), benign or malignant nasal tumors;\n* Important clinical comorbidities that may interfere with clinical efficacy results, including but not limited to active upper or lower respiratory tract infection, cystic fibrosis, eosinophilic granuloma with polyangiitis (Churg-Strauss syndrome), granuloma with polyangiitis (Wegener's granulomatosis), Young's syndrome, etc.;\n* Accompanied by other poorly controlled serious diseases or recurrent chronic diseases such as (but not limited to) active infection, cardiovascular disease, tuberculosis or other pathogen infection, diabetes, autoimmune diseases, HIV, hepatitis B, hepatitis C or parasitic diseases, malignant tumors, etc.;\n* Subjects with severe liver or kidney dysfunction, such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels \\> 2 times the upper limit of normal, and serum creatinine \\> the upper limit of normal;\n* Subjects with known or suspected immunosuppression, including those with a history of invasive opportunistic infections (such as tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pulmonary cystitis, aspergillosis), even if the infection has subsided;\n* Women who are pregnant or planning to become pregnant during the study period, or who are breastfeeding;\n* Subjects of childbearing age who do not wish to use medically approved effective contraception;\n* Subjects with a history of alcohol or drug abuse;\n* Subjects deemed by the investigator to have other medical or non-medical conditions that make them unsuitable for participation in this study.","75 Years",{"count":54,"type":22},48,[56],"NA","This is a single-center, randomized, double-blinded, placebo-controlled clinical trial in adults with moderate-to-severe chronic rhinosinusitis with nasal polyps (CRSwNP) who have no previous nasal surgery.\n\nThe purpose of this study is to evaluate the effectiveness and safety of using stapokibart for 4 weeks before endoscopic sinus surgery (ESS), compared with placebo before ESS.\n\nThe main questions this study aims to answer are:\n\n* Does preoperative stapokibart combined with endoscopic sinus surgery achieve better efficacy and comparable safety compared with surgery alone?\n* What influences four-week preoperative stapokibart administration has on pharmacodynamic data and intraoperative surgical parameters？\n* Is there a correlation between the efficacy of four-week stapokibart therapy and postoperative recurrence tendency after endoscopic sinus surgery?\n\nResearchers will randomly assign participants to receive either stapokibart or a placebo (an inactive substance that looks like the study drug) for 4 weeks before surgery. All participants will have the same standard endoscopic sinus surgery and will be followed for 48 weeks to check polyp status, symptoms, quality of life, and adverse events.\n\nThis study will provide evidence about whether short-term preoperative stapokibart improves surgical and long-term outcomes for adults with CRSwNP undergoing ESS.",[59],"Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)",[61,62,63,64,65,66,67,68,69,70,71,72],"chronic rhinosinusitis with nasal polyps","nasal polyps","stapokibart","endoscopic sinus surgery","type 2 inflammation","randomized controlled trial","surgical outcome","preoperative biologic therapy","disease recurrence","double-blinded method","clinical safety","treatment efficacy","2026-05-27",{"date":75,"type":36},"2026-06-01",{"date":75,"type":22},{"date":78,"type":22},"2028-12-31",{"name":42,"class":43},1,{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":4},"100615388","retinal-clinical-assessment-with-ai-derived-quantitative-information-100615388","NCT07291960","Retinal Clinical Assessment With AI-derived Quantitative Information","AI-derived Retinal Quantification Versus Routine Clinical Interpretation in Ophthalmic Assessment: a Randomized Controlled Trial","Inclusion Criteria:\n\nClinician Participants (Report Writers)\n\n1. Board-certified ophthalmologists or ophthalmology trainees (registrars or fellows) with clinical experience in interpreting fundus images.\n2. Capable of independently completing retinal clinical reports based on fundus photography.\n3. Willing and able to participate in the study tasks (report writing) under assigned study conditions.\n4. Able to provide informed consent.\n\nExpert Evaluators (Outcome Assessors)\n\n1. Senior ophthalmologists with at least 5 years of post-certification clinical experience.\n2. Not involved in the report-writing stage of the study.\n3. Willing to evaluate de-identified reports across predefined quality dimensions.\n4. Able to provide informed consent.\n\nFundus Images (Data Inputs)\n\n1. Retinal fundus photographs of sufficient quality for clinical interpretation.\n2. Images representing a range of common retinal findings (normal or abnormal).\n3. Previously collected, de-identified images with no patient-identifiable information.\n\nExclusion Criteria:\n\nClinician Participants\n\n1. Lack of experience in interpreting fundus images (e.g., interns, medical students).\n2. Prior involvement in the development, training, or validation of the AI system being tested.\n3. Inability to complete reporting tasks due to time constraints or technical limitations.\n4. Any condition that may interfere with ability to perform study tasks (e.g., prolonged absence).\n\nExpert Evaluators\n\n1. Participation in the intervention or control reporting arms.\n2. Prior exposure to or involvement in development of the AI system.\n3. Any conflict of interest affecting impartiality of report quality evaluation.\n\nFundus Images\n\n1. Poor-quality images with insufficient clarity for interpretation.\n2. Images containing artifacts or cropping that prevent accurate segmentation or assessment.\n3. Images with any remaining patient identifiers (excluded to maintain confidentiality).",true,{"count":90,"type":22},29,"21 Days","OBSERVATIONAL","This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment. Participating ophthalmologists and ophthalmology trainees will be randomly assigned to one of two groups. The intervention group will write clinical reports with access to automated quantitative measurements generated from fundus image analysis, including multiple retinal structural and vascular biomarkers. The control group will complete the same reporting tasks using only the original fundus images without AI-generated quantitative information.\n\nAll reports produced by both groups will be de-identified and independently evaluated by a separate panel of senior ophthalmologists who are blinded to group allocation. The expert evaluators will assess report accuracy, completeness, clarity, and overall clinical quality using predefined scoring criteria. The study aims to determine whether access to quantitative retinal biomarkers enhances clinicians' reporting performance and reduces reporting time during retinal assessment tasks.",[95,96,97,98,99,100,101,102],"no Obvious Abnormalities","Diabetic Retinopathy (DR)","AMD","Cup-to-disc Ratio Bigger Than 0.5","Pathological Myopia","Macular Hole","Epiretinal Membrane","Retinal Vein Occlusion (RVO)","2026-04-28",{"date":105,"type":36},"2026-04-29",{"date":107,"type":22},"2026-04-15",{"date":109,"type":22},"2026-05-15",{"name":42,"class":43},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":80},"100596024","phase-1-finotonlimab-combined-with-stapokibart-in-the-treatment-of-recurrentmetastatic-hnscc-100596024","NCT07040072","Finotonlimab Combined With Stapokibart in the Treatment of Recurrent\u002FMetastatic HNSCC","The Safety and Efficacy of Finotonlimab Combined With Stapokibart in the Treatment of Recurrent\u002FMetastatic Head and Neck Squamous Cell Carcinoma, a Phase Ib Study","LONG'E","Inclusion Criteria:\n\n1. Voluntarily sign the ICF;\n2. Recurrent\u002Fmetastatic HNSCC of the oral cavity, oropharyngeal, pharyngeal, and laryngeal regions;\n3. Male\u002Ffemale, ≥ 18 years old, ECOG 0\\~1;\n4. After PD-1 and platinum therapy, or PD-1 monotherapy, disease progression occurs within 24 weeks after the last ICI administration (as assessed by RECIST 1.1);\n5. Target lesion (RECIST 1.1);\n6. Previous PD-L1 expression test results may provide tissue for PD-L1 immunohistochemical testing;\n7. Expected to survive for more than 3 months;\n8. The main organ functions must meet the following requirements (laboratory test values within 7 days before enrollment must meet the following standards):\n\n   * Blood routine examination: (No blood transfusion, no use of granulocyte colony-stimulating factor, no medication correction within 14 days before screening): a) Neutrophils ≥ 1.5 × 10\\^9\u002FL; b) Platelets ≥ 75 × 10\\^9\u002FL; c) Hemoglobin ≥ 90g\u002FL; ② Biochemical examination: (No albumin transfusion within 14 days before screening): a) Blood creatinine ≤ 1.5 x upper limit of normal (ULN), or creatinine clearance rate\\>50 mL\u002Fmin; b) Serum total bilirubin ≤ 1.5 × ULN; c) Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN; ③ Coagulation function: a) International normalized ratio (INR) ≤ 2.3 or prothrombin time (PT) exceeding the normal control range ≤ 6 seconds.\n\nExclusion Criteria:\n\n1. Suitable for local treatment;\n2. Merge with other malignant tumors;\n3. Brain metastasis;\n4. If the toxicity does not recover to level 0-1 after surgery\u002Fradiotherapy\u002Fdrug treatment, excluding chronic toxicity;\n5. Allergic to known medication ingredients;\n6. Major surgeries, radiation therapy (excluding palliative care), chemotherapy, immunotherapy, and biologics within 4 weeks prior to enrollment;\n7. Received TKI, palliative surgery, and non-specific immunomodulatory therapy (such as thymosin and interferon) within 2 weeks before enrollment;\n8. Use immunosuppressive drugs within 4 weeks before enrollment (excluding short-term, local, and physiological dose hormone therapy);\n9. Patients with the following infection conditions:\n\n   Active infections require systemic use of antibiotics; Active mycobacterium tuberculosis infection (i.e. tuberculosis infection); Hepatitis C virus antibody (HCV Ab) positive and hepatitis C virus ribonucleic acid (HCV-RNA) positive; Hepatitis B virus deoxyribonucleic acid (HBV-DNA) ≥ 1000 IU\u002FmL; History of human immunodeficiency virus (HIV) infection or HIV antibody positivity during screening period.\n10. Uncontrollable pleural effusion, abdominal effusion, and pericardial effusion;\n11. Previous grade ≥ 3 irAE or grade ≥ 2 myocarditis;\n12. Have a serious history of cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    Major cardiovascular and cerebrovascular diseases (such as congestive heart failure, acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep vein thrombosis or pulmonary embolism, etc.) occurred within 6 months before the first administration; Corrected QT interval (QTcF)\\>480 msec; Echocardiography (ECHO) indicates that the subject's left ventricular ejection fraction (LVEF) \\\u003C 50%; New York Heart Association (NYHA) heart function classification ≥ 2; Clinically uncontrollable hypertension (If blood pressure is controlled with or without intervention, subjects can continue to be screened); Other cardiovascular and cerebrovascular diseases that have been evaluated by the researchers as unsuitable for participation in this study;\n13. Active autoimmune diseases;\n14. There is a significant risk of bleeding;\n15. Receive a live vaccine within 4 weeks before enrollment;\n16. During pregnancy or lactation, subjects with fertility do not receive contraceptive measures;\n17. The presence of mental illness may affect the conduct of clinical trials;\n18. History of organ transplantation or stem cell transplantation.",{"count":120,"type":22},10,[122],"PHASE1","This is a single-arm, phase Ib study involving HNSCC patients who had received first-line treatment with either PD-1 combined with platinum-based drugs or PD-1 monotherapy. The aim of the study is to evaluate the safety and efficacy of Finotonlimab in combination with Stapokibart in the treatment of recurrent\u002Fmetastatic HNSCC patients.",[125],"HNSCC","RECRUITING",{"date":128,"type":36},"2026-05-04",{"date":130,"type":36},"2025-10-09",{"date":132,"type":22},"2028-06",{"name":42,"class":43},{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":157,"leadSponsor":159,"locationsCount":80},"100635576","phase-2-selinexor-combined-with-reduced-dose-radiotherapy-for-early-stage-extranodal-nkt-cell-lymphoma-100635576","NCT07554482","Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK\u002FT-Cell Lymphoma","A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Selinexor Combined With Reduced-Dose Radiotherapy in the Treatment of Early-Stage Extranodal NK\u002FT-Cell Lymphoma","Inclusion Criteria:\n\n* Aged 18 to 75 years, regardless of gender.\n* Pathologically confirmed extranodal NK\u002FT-cell lymphoma (ENKTCL).\n* Ann Arbor stage I-II disease with primary lesion located in the nasal cavity or upper aerodigestive tract (UADT).\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n* Treatment-naïve patients with no prior radiotherapy, chemotherapy or targeted therapy.\n* Adequate major organ function as follows:\n* Hematopoietic function: absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelet count (PLT) ≥100×10⁹\u002FL, hemoglobin (Hb) ≥90 g\u002FL.\n* Hepatic function: total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN), alanine transaminase (ALT) \u002F aspartate transaminase (AST) ≤2.5×ULN.\n* Renal function: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60 mL\u002Fmin.\n* Cardiac function: left ventricular ejection fraction (LVEF) ≥50%.\n* Expected overall survival ≥6 months.\n* Voluntarily sign the written informed consent form.\n\nExclusion Criteria:\n\n* Non-nasal type ENKTCL, or primary lesions outside the upper aerodigestive tract (UADT), including skin, gastrointestinal tract, lung and other sites.\n* Patients with Ann Arbor stage III-IV disease.\n* Central nervous system involvement.\n* History of prior malignant tumors, excluding non-melanoma skin cancer or cervical carcinoma in situ cured for more than 5 years.\n* Active infections, including active hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infection.\n* Severe complications, such as uncontrolled diabetes mellitus and severe cardiopulmonary diseases.\n* Pregnant or lactating women.\n* Hypersensitivity or contraindication to any investigational drugs in this study.\n* Concurrent participation in other interventional clinical trials.",{"count":142,"type":22},34,[144],"PHASE2","Extranodal NK\u002FT-cell lymphoma (ENKTCL) is an Epstein-Barr virus-associated non-Hodgkin lymphoma with high incidence in Asia and Latin America. Approximately 70% of patients present with early-stage (I-II) disease confined to the upper aerodigestive tract. Radiotherapy at 50-56 Gy is the standard curative treatment, but high-dose radiotherapy causes severe toxicities including oral mucositis and xerostomia, while radiotherapy alone yields high systemic recurrence rates. Previous studies have confirmed the efficacy of P-GEMOX induction chemotherapy, verified the feasibility of reduced-dose radiotherapy in patients achieving complete response after chemotherapy, and demonstrated the radiosensitizing effect of selinexor via inhibiting IRF3-BARD1-BRCA1-mediated DNA damage repair. Moreover, international evidence supports the efficacy of 40 Gy radiotherapy combined with chemotherapy. Accordingly, this study hypothesizes that selinexor combined with 40 Gy reduced-dose radiotherapy following P-GEMOX induction chemotherapy can achieve equivalent efficacy to standard-dose radiotherapy, while markedly decreasing radiotherapy-related toxicities. This trial innovatively applies selinexor as a radiosensitizer in ENKTCL, fulfills the unmet clinical demand for efficacy-preserving toxicity reduction, and is well supported by preliminary data.",[147],"Extranodal NK\u002FT-cell Lymphoma",[149,150,151,152,153],"extranodal NK\u002FT-cell lymphoma","selinexor","XPO1 inhibitor","radiotherapy","reduced-dose radiotherapy","2026-04-21",{"date":103,"type":36},{"date":109,"type":22},{"date":158,"type":22},"2029-04-30",{"name":42,"class":43},{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":4,"eligibilityCriteria":166,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":174,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":80},"100633211","phase-2-pomalidomide-anti-pd-1-antibody-combined-with-selinexor-pps-in-relapsedrefractory-primary-central-nervous-system-diffuse-large-b-cell-lymphoma-100633211","NCT07523737","Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed\u002FRefractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma","Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed\u002FRefractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Clinical Study","Inclusion Criteria:\n\n* Histologically confirmed primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL).\n* Disease progression or relapse after prior treatment with high-dose methotrexate and\u002For BTK inhibitors.\n* Age between 18 and 75 years.\n* ECOG performance status score 0-4.\n* Expected overall survival \\> 3 months.\n* No known hypersensitivity to any study drug.\n* White blood cell count ≥ 3×10⁹\u002FL; absolute neutrophil count ≥ 1.0×10⁹\u002FL; platelet count ≥ 50×10⁹\u002FL.\n* Serum creatinine ≤ 1.5 mg\u002FdL; creatinine clearance ≥ 50 mL\u002Fmin.\n* ALT and AST ≤ 3× upper limit of normal (ULN); total bilirubin ≤ 2× ULN.\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* Presence of another malignant tumor requiring active pharmacological or surgical intervention at present;\n* Female patients who are pregnant or breastfeeding;\n* Patients (male or female) of reproductive potential who are unwilling to use or fail to use effective contraceptive measures;\n* Known hypersensitivity to any study drug or any excipient ingredients of these products;\n* Active infection (determined by the investigator);\n* History of immunodeficiency, including positive HIV status, other acquired or congenital immunodeficiency disorders, or history of organ transplantation;\n* Documented history of neurological or psychiatric disorders, including epilepsy or dementia;\n* Documented history of autoimmune diseases (except Hashimoto's thyroiditis or thyroid dysfunction);\n* Any severe comorbidity that, in the investigator's judgment, would compromise patient safety or interfere with the completion of the study.",{"count":168,"type":22},43,[144],"Primary central nervous system diffuse large B-cell lymphoma (PCNSL-DLBCL) is a highly aggressive malignancy accounting for over 80% of primary CNS lymphomas, with an annual incidence of 0.4-0.6 per 100,000 people globally and a rising trend in immunocompetent patients. First-line high-dose methotrexate-based chemotherapy causes severe toxicities and nearly 50% of patients relapse within 1-2 years, developing relapsed\u002Frefractory (R\u002FR) disease.\n\nTreatment options for R\u002FR PCNSL are scarce, with low response rates, median survival of only 3-6 months, and 5-year survival below 5%. The blood-brain barrier and tumor heterogeneity further worsen outcomes. This prospective, multicenter, single-arm phase II study evaluates the efficacy and safety of pomalidomide, PD-1 inhibitor, and selinexor (PPS) in R\u002FR PCNSL, aiming to provide a new effective treatment.",[172,173],"Primary Central Nervous System Lymphoma (PCNSL)","Diffuse Large B Cell Lymphoma (DLBCL)",[175,176,177,178,151,150],"diffuse large b cell lymphoma","primary central nervous system lymphoma","pomalidomide","PD-1 inhibitor","2026-04-10",{"date":107,"type":36},{"date":182,"type":36},"2026-04-01",{"date":184,"type":22},"2028-08-31",{"name":42,"class":43},{"id":187,"slug":188,"hasResults":12,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":199,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":80},"100633344","phase-1-combination-of-mitoxantrone-liposome-and-etoposide-dexamethasone-pegaspargase-and-golidocitinib-mepl-g-in-the-treatment-of-nkt-cell-lymphoma-associated-hemophagocytic-lymphohistiocytosis-nktcl-hlh-100633344","NCT07525466","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)","Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK\u002FT-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH): a Prospective, Multi-center, Single Arm, Phase Ib\u002FII Clinical Trial","Inclusion Criteria:\n\n* Histologically confirmed extranodal NK\u002FT-cell lymphoma.\n* Meeting the HLH-2004 diagnostic criteria (≥ 5 criteria).\n* Age ≥ 18 years, regardless of gender.\n* Negative HIV antigen or antibody.\n* Left ventricular ejection fraction (LVEF) ≥ 50% on cardiac echocardiography.\n* No active visceral bleeding (e.g., gastrointestinal, pulmonary, cerebral).\n* No uncontrolled infection (e.g., pulmonary infection, intestinal infection).\n* Negative HCV antibody; or positive HCV antibody with negative HCV RNA.\n* Negative HBsAg and negative HBcAb. If either is positive, peripheral blood HBV DNA load must be \\\u003C 1×10³ copies\u002FmL to be eligible.\n* Signed written informed consent and ability to understand and comply with all study requirements.\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) cardiac function class ≥ II;\n* Female patients who are pregnant or breastfeeding;\n* Known hypersensitivity to any of the study drugs;\n* Presence of other concurrent malignancies (except non-melanoma skin cancer);\n* Concurrent central nervous system lymphoma infiltration;\n* Severe psychiatric disorders or inability to comply with follow-up;\n* Severe renal dysfunction (glomerular filtration rate \\\u003C 15 mL\u002Fmin);\n* Severe liver cirrhosis (MELD score \\> 20);\n* History of acute or chronic pancreatitis;\n* Simultaneous participation in another clinical trial.",{"count":7,"type":22},[122,144],"Extranodal NK\u002FT-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes with no standard therapy. Notably, 10%-20% of patients develop secondary hemophagocytic lymphohistiocytosis (NKTCL-HLH), a life-threatening complication with median survival \\\u003C2 months and mortality over 90%. Current treatments fail to simultaneously control lymphoma and hyperinflammation, with poor tolerance and high resistance.\n\nThe JAK\u002FSTAT pathway drives EBV-induced inflammation and tumor progression. Golidocitinib, a selective JAK1 inhibitor, demonstrates potent anti-NKTCL activity and rapid inflammation control. Liposomal mitoxantrone offers targeted efficacy with lower toxicity, while etoposide, methylprednisolone, and pegaspargase provide synergistic anti-tumor and anti-HLH effects.\n\nThis study proposes the novel MEPL-G regimen (liposomal mitoxantrone, etoposide, methylprednisolone, pegaspargase, golidocitinib) for NKTCL-HLH. By targeting both HLH and NKTCL, this combination aims to achieve rapid disease control, improve tolerance, and prolong survival, addressing the unmet critical clinical need for this high-risk population.",[197,198],"Extranodal NK T Cell Lymphoma","Hemophagocytic Lymphohistiocytosis (HLH)",[149,200,201,202,203],"hemophagocytic lymphohistiocytosis","Mitoxantrone Liposome","Golidocitinib","JAK1","2026-04-07",{"date":206,"type":36},"2026-04-13",{"date":182,"type":36},{"date":209,"type":22},"2028-09-30",{"name":42,"class":43},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":23,"phases":221,"briefSummary":222,"conditions":223,"keywords":225,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":80},"100633305","antagonism-of-neostigmine-in-continuous-infusion-of-mivacurium-100633305","NCT07524959","Antagonism of Neostigmine in Continuous Infusion of Mivacurium","Antagonism of Neostigmine in Continuous Infusion of Mivacurium: a Randomised Controlled Trial","Inclusion Criteria:\n\n* 18 - 65 years old;\n* American Society of Anesthesiologists (ASA) physical stastus classification system: I-II;\n* Body mass index (BMI) 18.5 - 30 kg\u002Fm2\n* Patients with normal cholinesterase levels before the operation\n\nExclusion Criteria:\n\n* Refusal to participate in the study;\n* ASA classification of grade III or above;\n* Severe organ dysfunction, difficult airway or neurological muscle disorders;\n* Taking drugs that affect neuromuscular monitoring or neuromuscular conduction function;\n* Allergic to the test drug or having other contraindications;\n* Pregnant and lactating women","65 Years",{"count":220,"type":22},120,[56],"In this study, the antagonism of neostigmine, a cholinesterase inhibitor, on continuous infusion of mivacurium during foot and ankle surgery under general anesthesia was investigated, and the appropriate time point of antagonism was explored.",[224],"Neuromuscular Blocking Agents",[226,227,228,224],"Neuromuscular Monitoring","Mivacurium","Neostigmine","2026-04-06",{"date":206,"type":36},{"date":232,"type":22},"2026-05-01",{"date":234,"type":22},"2026-07-29",{"name":42,"class":43},{"id":237,"slug":238,"hasResults":12,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":245,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":254,"leadSponsor":256,"locationsCount":80},"100631370","phase-2-absorbable-drug-eluting-lacrimal-sac-stent-for-recurrent-chronic-dacryocystitis-100631370","NCT07499791","Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis","A Prospective, Multicenter, Randomized Controlled Trial of an Absorbable Drug-Eluting Lacrimal Sac Stent in Recurrent Chronic Dacryocystitis Undergoing Endoscopic Endonasal Dacryocystorhinostomy","Inclusion Criteria:\n\n* Diagnosed chronic dacryocystitis\n\nHistory of failed E-DCR or lacrimal intubation\n\nPreoperative dacryocystography showing lacrimal sac diameter ≥4 mm\n\nAge ≥18 years\n\nAble to consent and comply with procedures\n\nExclusion Criteria:\n\n* Nasal cavity structural disease: severe septal deviation, tumor, severe sinusitis\n\nLacrimal sac non-visualization on imaging\n\nLacrimal sac rupture, traumatic duct\u002Fbone injuries\n\nAllergy to mometasone furoate or PLA\u002FPGA polymers\n\nPoor general health, unable to tolerate surgery\n\nPsychiatric disorders or antipsychotic drug use\n\nUncontrolled hypertension, diabetes, or severe systemic diseases\n\nKeloid tendency\n\nCoagulation disorders\n\nPregnancy",{"count":244,"type":22},40,[144],"This study aims to evaluate the safety and effectiveness of an absorbable lacrimal sac drug-eluting stent placed at the osteotomy site during endoscopic endonasal dacryocystorhinostomy (E-DCR) in patients with recurrent chronic dacryocystitis. The stent is composed of absorbable polymer mesh coated with mometasone furoate to reduce postoperative inflammation and adhesion, maintain ostium patency, and improve surgical outcomes. A total of 40 patients will be randomized 1:1 to receive either the absorbable stent or conventional packing with routine postoperative intranasal budesonide therapy.",[248],"Chronic Dacryocystitis",[248],"2026-03-25",{"date":252,"type":36},"2026-03-30",{"date":232,"type":22},{"date":255,"type":22},"2027-12-01",{"name":42,"class":43},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":12,"sex":17,"minAge":264,"maxAge":265,"enrollmentInfo":266,"targetDuration":4,"studyType":23,"phases":268,"briefSummary":269,"conditions":270,"keywords":272,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":282,"leadSponsor":284,"locationsCount":80},"100629291","auricular-acupressure-for-reducing-postoperative-emergence-agitation-in-preschool-children-100629291","NCT07472764","Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children","Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children Undergoing Adenoidectomy: A Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* (1) American Society of Anesthesiologists (ASA) physical status classification of I to III; (2) Children aged 3 to 6 years scheduled for elective adenoidectomy; (3) No damage to the epidermis of the external ear.\n\nExclusion Criteria:\n\n* (1) Children taking anti-anxiety or antidepressant medications; (2) Children with a history of psychiatric disorders or current psychiatric abnormalities; (3) Children with cognitive deficits or cognitive and intellectual developmental disorders; (4) Children with allergies to auricular acupressure beads; (5) Participation in other clinical trials within the past three months.","3 Years","6 Years",{"count":267,"type":22},110,[56],"This study investigates whether auricular acupressure can reduce postoperative emergence agitation among preschool children following adenoidectomy.",[271],"Emergence Agitation",[273,274,275,276,277],"Auricular Acupressure","Emergence agitation","Postoperative pain","non-invasive Traditional Chinese Medicine","Pediatric Anesthesia","2026-03-12",{"date":280,"type":36},"2026-03-16",{"date":182,"type":22},{"date":283,"type":22},"2026-09-30",{"name":42,"class":43},{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":4,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":80},"100624672","evaluation-of-the-efficacy-of-red-light-in-adult-patients-with-high-and-extreme-myopia-100624672","NCT07412678","Evaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia","Inclusion Criteria:\n\nAged 18 to 45 years old. Spherical equivalent refraction of -6.00D to -20.00D in one or both eyes measured by cycloplegic computer optometry.\n\nIntraocular pressure (IOP) ranging from 10 to 21 mmHg. Clear crystalline lens (cataract excluded). No active ocular inflammation, history of ocular trauma or surgery, and no ocular or systemic organic diseases that affect visual acuity changes.\n\nVoluntarily participate in the study and sign the informed consent form. Willing to use the Tongren Myopia and Amblyopia Therapeutic Apparatus (Patent No.: 202022533301.4, manufactured by Hunan Yifan Technology Co., Ltd.) or accept the above-mentioned control treatment.\n\nExclusion Criteria:\n\nPatients with the following ocular diseases: choroidal neovascularization, macular hemorrhage, macular schisis, extensive chorioretinal atrophy, and refractive media opacity (such as corneal lesions, lens opacity, etc.).\n\nSubjects with systemic or immune diseases that affect compliance, including tumors, heart diseases (with implanted electronic devices such as cardiac pacemakers), severe hepatic and renal diseases, epilepsy, autoimmune diseases, etc.\n\nSubjects with mental disorders that interfere with the implementation of intervention measures in this trial.\n\nHypersensitivity to cycloplegic agents. Other circumstances deemed inappropriate for participation in the trial by the investigator for safety reasons or the patient's benefit.","45 Years",{"count":293,"type":22},128,[56],"This study, led by Jie ying from the Ophthalmology Department of Beijing Tongren Hospital Affiliated to Capital Medical University, is a researcher-initiated clinical trial (IIT) designed to evaluate the therapeutic efficacy of low-intensity red light therapy in adult patients with high myopia (spherical equivalent ≤ -6.00D) and extreme myopia (spherical equivalent ≤ -10.00D). With the escalating global prevalence of high and extreme myopia-especially in East Asia including China-and pathological myopia becoming a leading cause of irreversible blindness in Chinese adults, red light therapy has shown promising effects in slowing myopia progression in children but lacks clinical evidence for adult populations, which constitutes the core rationale for this research.",[297],"Myopia","2026-02-09",{"date":300,"type":36},"2026-02-17",{"date":302,"type":22},"2026-02-12",{"date":304,"type":22},"2027-03-11",{"name":42,"class":43},{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":12,"sex":17,"minAge":265,"maxAge":18,"enrollmentInfo":313,"targetDuration":4,"studyType":23,"phases":315,"briefSummary":316,"conditions":317,"keywords":318,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":325,"leadSponsor":326,"locationsCount":80},"100608981","development-of-bioluminescent-myopia-prevention-and-control-instrument-and-evaluation-of-its-effect-on-myopia-100608981","NCT07208617","Development of Bioluminescent Myopia Prevention and Control Instrument and Evaluation of Its Effect on Myopia","Efficacy Superiority Trial of Red Light Myopia Control Device Based on LED Light Source","Inclusion Criteria:\n\n* Willing to use myopia treatment devices based on LED light sources or fake light sources Aged 6-18 years old For both eyes, the myopic spherical equivalent refraction after cycloplegic computerized refraction: -0.50D to -6.00D, and astigmatism ≤ 2.50D Spherical equivalent anisometropia of both eyes ≤ 2.50D Corrected visual acuity (for both near and far) ≥ 1.0 Intraocular pressure (IOP) 10-21mmHg No active ocular inflammation, no history of ocular trauma, no history of ocular surgery, and no ocular or systemic organic diseases that affect visual changes Voluntarily participate in this project and sign the informed consent form The subject has not used other myopia control methods in the past six months Have records of refractive error and axial length measurements six months before enrollment\n\nExclusion Criteria:\n\n* Subjects with systemic diseases or immune diseases that affect compliance, such as tumors, heart diseases (including those with implanted electronic devices in the body, such as cardiac pacemakers), severe liver and kidney diseases, epilepsy, and autoimmune diseases Subjects with mental illnesses that affect the implementation of the intervention measures in this trial Subjects with refractive media opacity (corneal lesions, lens opacity, etc.) or ocular diseases: macular diseases, moderate to severe dry eye, corneal diseases, cataracts, vitreoretinal diseases, infectious conjunctivitis, uveitis, optic nerve damage, congenital optic nerve dysplasia, or other ocular diseases Subjects allergic to cycloplegics Other circumstances where the researcher deems it inappropriate for the subject to participate in the trial for safety reasons or in the interest of the patient",{"count":314,"type":22},206,[56],"Based on the Tongren Myopia and Amblyopia Therapeutic Apparatus (a 650nm low-level red-light device) developed by the research team in the previous phase, the device was modified by replacing the light source with LED light. Subsequently, a population study was conducted to evaluate its efficacy and safety in myopia prevention and control.",[297],[297,319,320],"Red-light","LED light","2026-02-06",{"date":323,"type":36},"2026-02-10",{"date":302,"type":22},{"date":283,"type":22},{"name":42,"class":43},{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":334,"targetDuration":4,"studyType":23,"phases":336,"briefSummary":337,"conditions":338,"keywords":339,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":350,"locationsCount":80},"100621538","phase-2-application-of-zanubrutinib-based-combination-regimens-in-the-treatment-of-newly-diagnosed-diffuse-large-b-cell-lymphoma-100621538","NCT07371923","Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma","Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma: A Phase II, Prospective, Single-center, Single-arm Clinical Study","Inclusion Criteria:\n\n* Pathologically confirmed diffuse large B-cell lymphoma (DLBCL);\n* Have a \"measurable lesions\" ;\n* Have at least one of the following risk factors, including: IPI score ≥2 points, ABC subtype, double-expressor lymphoma, double-hit lymphoma, CD5-positive DLBCL, MCD subtype, N1 subtype, A53 subtype, extranodal lesions ≥2, special site involvement, such as central nervous system CNS, breast, testis, ovary, uterus, bone marrow, vitreoretinal, paraspinal, paranasal sinuses and intravascular, etc.\n* ECOG score 0-3;\n* Expected survival time for 3 months or more;\n* White blood cell count ≥3 x 10e9\u002FL, the platelet count≥50 x 10e9\u002FL; 1.5 mg\u002FdL or less of serum creatinine, creatinine clearance≥50 ml\u002Fmin; ALT, AST 3 x ULN or less, total bilirubin 2 x ULN or less.\n\nExclusion Criteria (the subject should not have any one of the following):\n\n* currently suffering from other malignant tumor;\n* ever received any treatments for lymphoma, except for short-term use of corticosteroids;\n* Allergic to any kind of study drug;\n* Active infection or uncontrol of HBV infection, HIV\u002FAIDS or other serious infectious diseases;\n* Pregnancy and lactation women of childbearing age and are reluctant to take contraception subjects;\n* Researchers think that the subject does not fit to participate in this study.",{"count":335,"type":22},50,[144],"Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Currently, the first-line treatment regimen based on R-CHOP can only achieve clinical cure for 50% to 60% of patients. Previous studies have shown that patients with high-risk factors have a poor response to R-CHOP treatment and need further improvement. These high-risk factors include: IPI score ≥2 points, ABC subtype, double-expressing lymphoma, double-hit lymphoma, CD5-positive DLBCL, MCD subtype, N1 subtype, A53 subtype, extranodal lesions ≥2, special site involvement, such as central nervous system CNS, breast, testis, ovary, uterus, bone marrow, vitreoretinal, paraspinal, paranasal sinuses and intravascular, etc. Patients with DLBCL accompanied by high-risk factors also have a significantly increased risk of secondary CNS infiltration during recurrence. In previous RCHOP+X research strategies, only the combination of polatuzumab achieved significant 2-year PFS benefits in the overall population. None of the other studies achieved significant PFS benefits in the overall population. Therefore, the latest version of the CSCO guidelines recommends the Pola-R-CHP regimen as the first-line treatment for primary DLBCL. However, there is still considerable room for improvement in the survival of DLBCL patients with high-risk factors in clinical practice. Therefore, the strategy of the Pola-R-CHP-based combined with X regimen in high-risk DLBCL patients with specific risk factors can be explored subsequently.\n\nThe Phoenix study for young double expression of lymphoma patients, R - CHOP combined with BTK inhibitors can significantly improve the patient's survival, the subsequent omics data analysis indicates that MCD subtype, N1 subtypes and BN2 subtype can significantly benefit from BTK inhibitors. In addition, given that the proportion of MCD subtypes is high in most extranodal DLBCL patients and secondary CNS involvement is prone to occur, BTK inhibitors can effectively penetrate the blood-brain barrier (BBB) and have both preventive and therapeutic effects on CNS lesions. Therefore, exploring the application of BTK inhibitor zanubrutinib combined with R-CHOP or Pola-R-CHP regimens in high-risk DLBCL patients with specific risk factors (or zanubrutinib combined with rituximab and high-dose MTX in primary central nervous system DLBCL) has good application prospects. It is conducive to further improving the prognosis of such high-risk patients. Therefore, this study aimed to explore the efficacy and safety of the BTK inhibitor zanubrutinib combined with Pola-R-CHP regimen (or zanubrutinib combined with rituximab and high-dose MTX in primary central nervous system DLBCL, etc.) in patients of DLBCL with specific risk factors (IPI score two points or more, ABC subtypes, double expressor lymphoma, double hit lymphoma, CD5 positive DLBCL, MCD subtypes, N1 subtypes, A53 subtypes, extranodal lesions of 2 or more, special locations involved, such as the central nervous system (CNS, breast, testes).",[173],[340,341,342,343],"diffuse large b cell lymphoma (DLBCL)","BTK inhibitors","zanubrutinib","high-risk factors","2026-01-19",{"date":346,"type":36},"2026-01-28",{"date":348,"type":36},"2025-11-20",{"date":184,"type":22},{"name":42,"class":43},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":23,"phases":360,"briefSummary":361,"conditions":362,"keywords":364,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":374,"locationsCount":375},"100620290","phase-4-application-of-orelabrutinib-with-or-without-cd20-monoclonal-antibody-in-previously-untreated-marginal-zone-lymphoma-100620290","NCT07355699","Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma","Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma:A Phase II, Prospective, Multicenter, Single-Arm Clinical Study","Inclusion Criteria:\n\n* Age ≥ 18 years;\n* Pathologically confirmed marginal zone lymphoma;\n* Presence of evaluable lesions;\n* Meets indications for treatment: Fulfills the GELF criteria OR has disease-related clinical symptoms\u002Forgan function impairment;\n* Patients who are unsuitable for local radiotherapy, refuse local radiotherapy, or have disease progression after local therapy. Cases considered unsuitable for local radiotherapy include the following:\n\nGastric MALT MZL, Ann Arbor stage I, that is H. pylori-negative, or H. pylori-positive gastric MALT MZL (Ann Arbor stage I) with poor response to H. pylori eradication therapy;\n\nNon-gastric MALT and nodal MZL in Ann Arbor non-contiguous stage II or stages III-IV;\n\nSMZL;\n\nGastric MALT classified as Lugano II2, IIE, or IV stage;\n\nPatient intolerance to radiotherapy;\n\nOther MZL patients deemed unsuitable for local radiotherapy by the investigator.\n\n* ECOG score of 0-3;\n* Expected survival time ≥ 3 months;\n* Ability to provide signed informed consent.\n\nExclusion Criteria:\n\n* Currently diagnosed with another malignant tumor;\n* Central nervous system involvement by lymphoma or transformation to a higher grade;\n* Allergy to any of the investigational drugs;\n* Active infection or uncontrolled HBV infection, HIV\u002FAIDS, or other serious infectious diseases;\n* Pregnancy, lactating women, or subjects of childbearing potential unwilling to use contraception;\n* Other situations deemed by the investigator as unsuitable for participation in this trial.",{"count":359,"type":22},88,[25],"This study focuses on treatment-naïve marginal zone lymphoma (MZL) patients and aims to investigate the efficacy and safety of orelabrutinib combined with or without CD20 monoclonal antibody.\n\nThis is a single-arm study without a control group. All subjects will receive orelabrutinib treatment but will be stratified based on disease stage and clinical characteristics into the following two groups:\n\n1. Stage I MZL Patient Group (Monotherapy Group) Treatment regimen: Orelabrutinib monotherapy. Dosage and administration: Orelabrutinib 150mg, once daily (qd), taken continuously for 21 days per treatment cycle (d1-d21), for a total of 6 cycles (C1-C6).\n\n   Target population: Patients with Ann Arbor Stage I gastric MALT MZL, including H. pylori-negative patients or those with unsatisfactory response after anti-H. pylori therapy, as well as other Stage I MZL patients unsuitable for local radiotherapy.\n\n   Sample size: 50 cases.\n2. Stage II-IV MZL Patient Group (Combination Therapy Group) Treatment regimen: Orelabrutinib combined with a CD20 monoclonal antibody. Dosage and administration: Orelabrutinib 150mg, once daily (qd), taken continuously for 21 days per treatment cycle (d1-d21), for a total of 6 cycles (C1-C6). CD20 monoclonal antibody (either Rituximab 375mg\u002Fm², intravenous infusion, Day 1 of each cycle, C1-C6; or Obinutuzumab 1000mg, intravenous infusion, on Days 1, 8, and 15 of Cycle 1 \\[C1\\], and on Day 1 of Cycles 2-6 \\[C2-C6\\]).\n\nTarget population: Patients with Ann Arbor Stage II-IV non-gastric MALT MZL, nodal MZL, splenic marginal zone lymphoma (SMZL), and other Stage II-IV MZL patients unsuitable for local radiotherapy.\n\nSample size: 38 cases.",[363],"Marginal Zone Lymphoma(MZL)",[365,366,367],"Marginal Zone Lymphoma","Orelabrutinib","CD20 Monoclonal Antibody","2026-01-13",{"date":370,"type":36},"2026-01-21",{"date":372,"type":36},"2025-11-25",{"date":78,"type":22},{"name":42,"class":43},3,{"id":377,"slug":378,"hasResults":12,"nctId":379,"briefTitle":380,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":88,"sex":17,"minAge":265,"maxAge":382,"enrollmentInfo":383,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":398,"locationsCount":80},"100617794","clinical-study-on-the-effectiveness-of-diverse-segments-defocus-optimization-in-spectacle-lenses-for-slowing-myopia-progression-100617794","NCT07323251","Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression","Inclusion Criteria:\n\n* Age 6-14 years\n* Myopic spherical equivalent refraction between -0.75D and -4.00D (inclusive of -0.75D and -4.00D, based on cycloplegic refraction)\n* Astigmatism ≤1.50D\n* Anisometropia ≤1.50D\n* Best-corrected visual acuity (BCVA) reaching 5.0 (0.00 LogMAR) or better in both eyes; monocular BCVA reaching 5.0 (0.00 LogMAR) or better after wearing myopic defocus spectacles\n* Absence of organic ocular diseases\n* No history of myopia control treatment within the past three months, including orthokeratology, progressive multifocal lenses, peripheral defocus spectacle lenses, bifocal spectacle lenses, defocus-designed soft hydrophilic contact lenses, other myopia control medications, or light-therapy devices\n* Voluntary participation in this clinical study and provision of signed informed consent\n\nExclusion Criteria:\n\n* History of ocular trauma or surgery\n* Systemic diseases affecting visual function\n* Inability to cooperate with examinations\n* Poor compliance\n* Inability to adhere to wearing requirements and follow-up visits during the trial period","14 Years",{"count":220,"type":22},[56],"Clinical Trial\n\nThe goal of this clinical trial is to evaluate the effectiveness of two types of Diverse Segments Defocus Optimization (D.S.D.O.) spectacle lenses in slowing myopia progression in children. It will also assess the safety of these lenses. The main questions it aims to answer are:\n\nDo D.S.D.O. lenses reduce the progression of myopia as measured by changes in cycloplegic refraction and axial length? What adverse events do participants experience when wearing D.S.D.O. lenses? Researchers will compare two optical designs of D.S.D.O. lenses (Intervention Group1: Design 1; Intervention Group2: Design 2) to determine their relative efficacy in controlling myopia progression.\n\nParticipants will:\n\nWear assigned D.S.D.O. lenses daily for 12 months (except during sleep or unavoidable situations).\n\nAttend clinic visits at baseline, 3, 6, 9, and 12 months for comprehensive eye examinations.\n\nMaintain a diary recording daily wear time, visual symptoms, and any adverse events.",[387,388,389,390,391],"Children With Myopia","Treatment","Multizone Lens Design for Myopic Defocus","Visual Quality","Efficacy","2025-12-23",{"date":394,"type":36},"2026-01-07",{"date":396,"type":36},"2024-08-02",{"date":283,"type":22},{"name":42,"class":43},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":405,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":407,"targetDuration":4,"studyType":23,"phases":408,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":413,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":418,"locationsCount":80},"100539158","phase-2-study-of-cm310-in-patients-with-uncontrolled-seasonal-allergic-rhinitis-100539158","NCT06300203","Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis","The Efficacy and Safety of Humanized Antibody Targeting the Interleukin-4 Receptor Alpha Subunit (IL-4Rα) in Patients With Uncontrolled Seasonal Allergic Rhinitis Under Standard Treatment： A Randomized, Double-Blind, Placebo-controlled IIT Study","MEGREZ","Inclusion Criteria:\n\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Have any condition that are not suitable for participating in this study.",{"count":220,"type":22},[144],"Allergic rhinitis (AR) is a non-infectious chronic inflammatory disease of the nasal mucosa mainly mediated by immunoglobulin E after exposure to allergens in atopic individuals. The typical symptoms of AR are paroxysmal sneezing, watery rhinorrhea, itching, and nasal congestion, which may be accompanied by ocular symptoms, including eye itching, tearing, redness, and burning sensation, which are more common in patients with hay fever allergies. Bronchial asthma is associated with bronchial asthma in 40% of patients with AR, suggesting a comorbid feature of allergic disease.",[411],"Seasonal Allergic Rhinitis","2025-09-20",{"date":414,"type":36},"2025-09-25",{"date":416,"type":36},"2024-03-18",{"date":38,"type":22},{"name":42,"class":43},{"id":420,"slug":421,"hasResults":12,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":428,"studyType":92,"phases":4,"briefSummary":429,"conditions":430,"keywords":434,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":412,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":441,"locationsCount":80},"100488779","retinal-vascular-manifestations-in-patients-with-common-internal-diseases-on-octa-tomography-angiography-100488779","NCT05644548","Retinal Vascular Manifestations in Patients With Common Internal Diseases on OCTA Tomography Angiography","Retinal Vascular Manifestations in Patients With Common Internal Diseases on Optical Coherence Tomography Angiography","Inclusion Criteria:\n\n* Patients with hypertension\n* Or patients with diabetes\n* Or patients with dyslipidemia\n* Agree to participate in this study\n\nExclusion Criteria:\n\n* Patients with malignant tumors\n* Patients with autoimmune diseases\n* Patients with immunodeficiency disease\n* Disagree to participate in this study",{"count":427,"type":22},300,"5 Years","Hypertension, diabetes mellitus, and dyslipidemia are common internal diseases, and all diseases are atherosclerosis risk factors. Previous studies applied color fundus photography to analyze retinal vascular changes (including exudation, hemorrhage, neovascularization, etc.) in patients with hypertension or diabetes, but the examination results could not be quantified.\n\nThis study intends to apply optical coherence tomography angiography (OCTA) to examine retinal vessels. This method has the following advantages: 1) It can quantify vascular changes, and 2) It is noninvasive and reproducible for patients' follow-up.\n\nThis study was designed to investigate retinal vascular changes in patients with hypertension, diabetes, and dyslipidemia on OCTA. We will collect the patients' general information (gender, age), comorbidities, medications, blood lipids, blood glucose, carotid ultrasound, ankle-brachial index, ambulatory blood pressure monitoring, color fundus photography, and OCTA results. We will follow up with the patients for five years and conduct the mentioned examinations once a year. We will also investigate the correlation between systemic atherosclerosis (such as coronary artery stenosis, and carotid artery stenosis) and retinal vasculopathy in patients with these diseases.",[431,432,433],"Hypertension","Diabetes Mellitus","Dyslipidemias",[435,431,436,433],"OCTA","Diabetes",{"date":414,"type":36},{"date":439,"type":36},"2022-03-01",{"date":78,"type":22},{"name":42,"class":43},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":4,"eligibilityCriteria":448,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":449,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":4},"100578991","ganyan-1-in-dry-eye-100578991","NCT06818487","Ganyan-1 in Dry Eye","Ganyan-1 in Dry Eye: A Randomized Clinical Trial","Inclusion Criteria:\n\n1\\. Age \\>=18 and Age \\\u003C=70, complaint of DED symptoms for 6 months or longer at screening.\n\n3\\. ocular surface disease index (OSDI) score of 25 or higher. 4. tear film breakup time (TFBUT) of 5 seconds or less. 5. Schirmer I test without anesthesia of 5 mm or more at 5 minutes. 6. CFS score of 4 or higher.\n\nExclusion Criteria:\n\n1. History systemic autoimmune diseases and ocular\u002Fperiocular malignancy.\n2. Clinically relevant slitlamp findings or abnormal lid anatomy.\n3. Active ocular allergies and active infection.\n4. Pregnant or lactating women.",{"count":450,"type":22},219,[56],"Ganyan -1 for the patients with dry eye",[28,454],"TCM",[30,454,456],"RCT","2025-06-19",{"date":459,"type":36},"2025-06-25",{"date":461,"type":22},"2025-07-01",{"date":463,"type":22},"2027-02-01",{"name":42,"class":43},{"id":466,"slug":467,"hasResults":12,"nctId":468,"briefTitle":469,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":471,"targetDuration":4,"studyType":23,"phases":473,"briefSummary":474,"conditions":475,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":477,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":4},"100584830","phase-2-a-prospective-multicenter-multicohort-phase-ii-study-evaluating-the-efficacy-and-safety-of-preoperative-neoadjuvant-treatment-with-a-pd-1-inhibitor-in-combination-with-chemotherapy-in-locally-advanced-laryngeal-and-hypopharyngeal-squamous-cell-carcinoma-100584830","NCT06894459","A Prospective, Multicenter, Multicohort Phase II Study: Evaluating the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with locally advanced laryngeal and hypopharyngeal squamous cell carcinoma who have been definitively diagnosed by histology and\u002For cytology, and whose TN staging meets: T1-4a, N0-3.\n* No prior treatment received.\n* Cisplatin-tolerant.\n* Age ≥18 years.\n* ECOG performance status of 0-1.\n* Measurable disease as defined by RECIST v1.1.\n* Normal organ function.\n* Women and men of reproductive potential must agree to use appropriate contraceptive methods throughout the study period and for 180 days after the last study treatment.\n* Male participants must not donate sperm during the entire study period and for 180 days after the last study treatment.\n\nExclusion Criteria:\n\n* T stage is T4b.\n* Presence of distant metastasis.\n* Received live vaccines within 30 days prior to enrollment.\n* Diagnosed with an immunodeficiency or received systemic corticosteroid treatment or any other form of immunosuppressive therapy within 7 days prior to enrollment.\n* Have radiologically detectable (even if asymptomatic and\u002For previously treated) central nervous system metastases and\u002For carcinomatous meningitis.\n* Have not fully recovered from surgery or from toxicities or complications due to interventions before starting the study.\n* Have a history of allogeneic tissue\u002Fsolid organ transplantation.\n* Have had a severe hypersensitivity reaction (≥Grade 3) to PD-1 inhibitors, chemotherapy, or any of their excipients, or radiotherapy.\n* Have an active autoimmune disease that has required systemic therapy within the past 2 years.\n* Have a history of (non-infectious) pneumonitis that required treatment with corticosteroids.\n* Have a history of infection with the Human Immunodeficiency Virus (HIV).\n* Have a medical history that could confound study results or interfere with the participant during the study period.\n* Have a known history of psychiatric disorders or substance abuse.",{"count":472,"type":22},180,[144],"Head and neck squamous cell carcinoma (HNSCC) refers to a series of tumors that occur in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, paranasal sinuses, thyroid gland, and salivary glands. Malignant tumors of the head and neck account for approximately 19.9% to 30.2% of all tumors in the body, ranking sixth in incidence among all malignant tumors, with over 90% being squamous cell carcinoma in terms of pathological type. The treatment of head and neck squamous cell carcinoma is primarily surgical. Early-stage cases can achieve a cure through simple surgical resection or radiotherapy. For locally advanced and late-stage cases, a combination of surgery with radiotherapy or chemotherapy can yield satisfactory therapeutic effects. However, most patients with head and neck tumors present at a locally advanced (Stage III to IVB) or late stage, possibly having lost the opportunity for surgery and can only opt for a comprehensive treatment mainly based on radiochemotherapy. Current data show that with standard treatment, the 5-year survival rates for patients with early-stage, locally advanced, and metastatic head and neck squamous cell carcinoma are 80%, 50%, and 25%, respectively. Fifty to sixty percent of newly diagnosed subjects cannot be cured and experience recurrence or metastasis within 3 years. For patients with recurrent or metastatic disease after first-line treatment failure, the median survival time with chemotherapy is only 6 to 9 months, with a 1-year survival rate of 5% to 33% and a 5-year survival rate of merely 3.6%. Laryngeal cancer and hypopharyngeal cancer hold unique significance among head and neck tumors because they not only threaten patients' lives but can also significantly affect their quality of life, particularly the preservation of laryngeal function. Laryngeal function includes voice production, swallowing, and breathing, and the loss of these functions can lead to a severe decline in quality of life. Traditionally, surgical resection has been the main treatment for these cancers, but total laryngectomy can result in permanent voice loss and significant psychological and social impacts. Therefore, how to effectively control the tumor while preserving laryngeal function has become an important goal of treatment.\n\nPD-L1 is a key negative regulator of self-reactive T cells and plays a role in maintaining peripheral immune tolerance and suppressing autoimmunity in various ways, leading to T cell exhaustion and dysfunction, and allowing tumor cells to evade immune surveillance. PD-1\u002FPD-L1 monoclonal antibodies restore the function of tumor-specific T cells by blocking the binding of PD-1 to PD-L1, thereby enhancing antitumor immunity and are now used to treat a variety of tumors. The efficacy of PD-1 inhibitors as neoadjuvant therapy in head and neck squamous cell carcinoma is not yet clear. However, given the good therapeutic effects of immunotherapy in head and neck squamous cell carcinoma, induction therapy with PD-1 inhibitors is considered to have promising clinical application prospects.\n\nIn summary, we hypothesize that compared with the traditional TPF (docetaxel, cisplatin, and fluorouracil) neoadjuvant chemotherapy regimen, a PD-1 inhibitor combined with chemotherapy regimen may be safer and more effective and easier to apply in clinical practice. At present, there are no reports of studies on the use of PD-1 inhibitors combined with chemotherapy regimens for locally advanced, resectable head and neck squamous cell carcinoma patients, either domestically or internationally. We plan to investigate the efficacy and safety of neoadjuvant treatment with PD-1 inhibitors combined with chemotherapy for resectable head and neck squamous cell carcinoma patients in China, to provide a basis for future neoadjuvant treatment regimens.",[476],"Head and Neck Cancers","2025-04-27",{"date":479,"type":36},"2025-04-30",{"date":481,"type":22},"2025-05-08",{"date":483,"type":22},"2028-12-01",{"name":42,"class":43},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":489,"acronym":4,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":491,"targetDuration":4,"studyType":23,"phases":493,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":505,"locationsCount":80},"100577673","phase-4-a-cohort-study-on-biomarkers-to-predict-the-efficacy-of-biologics-for-chronic-rhinosinusitis-with-nasal-polyps-100577673","NCT06801353","A Cohort Study on Biomarkers to Predict the Efficacy of Biologics for Chronic Rhinosinusitis with Nasal Polyps","Inclusion Criteria:\n\n1. Age 18-75 years old.\n2. With bilateral chronic rhinosinusitis with nasal polyposis.\n3. Nasal Polyp Score ≥4 (minimum score of 2 per nasal cavity) at baseline.\n4. Nasal congestion score ≥2 at baseline.\n5. Patients who have received systemic corticosteroids (SCS) treatment within 2 years before screening, and\u002For have contraindications or intolerance to SCS treatment, and\u002For received surgical for nasal polyps more than 6 months before screening.\n6. Have been using intranasal corticosteroids (INCS) at a stable dose for at least 4 weeks before screening.\n7. Symptoms of nasal obstruction and additional symptoms such as loss of smell or rhinorrhea should be present for at least 4 weeks before screening.\n8. Good adherence.\n\nExclusion Criteria:\n\n1. Not enough washing out period for prior biological therapy (within 10 weeks or 5 half-lives \\[whichever is longer\\] before baseline).\n2. Use of systemic immunosuppressants for inflammatory diseases or autoimmune diseases within 8 weeks or 5 half-lives before baseline (whichever is longer).\n3. Initiation of leukotriene receptor antagonist treatment, oral glucocorticoid treatment, or traditional Chinese medicine treatment for chronic rhinosinusitis within 4 weeks before baseline.\n4. Subjects who have undergone surgery that changed the nasal structure and cannot be evaluated for Nasal Polyp Score.\n5. Participants with a forced expiratory volume in 1 second (FEV1) ≤50% of predicted normal during screening\u002Frun-in period.\n6. Hypersensitivity to MFNS or anti-IL-4R monoclonal antibodies or stapokibart components.\n7. Concomitant with other poorly controlled serious diseases or recurrent chronic diseases.\n8. Women who are pregnant, breastfeeding, or planning either during the study.",{"count":492,"type":22},90,[25],"Recently, several biologic therapies have become available for treating chronic rhinosinusitis with nasal polyps (CRSwNP). However, not every patient responds to these treatments. This clinical trial aims to develop a non-invasive predictive model to help determine how effective IL-4Rα targeted monoclonal antibody therapy will be for individuals with CRSwNP.",[496,497,498],"Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)","Biological Therapy","Biomarkers","2025-02-05",{"date":501,"type":36},"2025-02-06",{"date":503,"type":22},"2025-02-01",{"date":35,"type":22},{"name":42,"class":43},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":4,"eligibilityCriteria":512,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":513,"targetDuration":4,"studyType":23,"phases":515,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":523,"leadSponsor":524,"locationsCount":4},"100577089","phase-2-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-salvage-preoperative-pd-1-inhibitor-combined-with-chemotherapy-neoadjuvant-therapy-in-recurrent-and-metastatic-lpscchpscc-100577089","NCT06793761","A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC\u002FHPSCC","A Prospective, Multicenter, Randomized Controlled Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic Laryngeal and Hypopharyngeal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with histologically and\u002For cytologically diagnosed squamous cell carcinoma of the larynx and hypopharynx\n* Patients with recurrence of primary lesions or second primary lesions after definitive treatment\n* At least 6 months from the end of the last platinum-containing treatment\n* Cisplatin-tolerant\n* Age ≥ 18 years\n* ECOG 0-1\n* Measurable disease as defined by RECIST v1.1\n* Normal organ function\n* Female and male participants of reproductive potential must agree to use appropriate contraception throughout the study and for 180 days after the last study treatment\n* Male participants must not donate sperm throughout the study and for 180 days after the last study treatment\n\nExclusion Criteria:\n\n* T stage after relapse (rT) is T4b\n* Presence of distant metastasis\n* Received live vaccines within 30 days before enrollment\n* Diagnosed with immunodeficiency or received systemic steroids or any other form of immunosuppressive therapy within 7 days before enrollment\n* Have radiologically detectable (even if asymptomatic and\u002For previously treated) central nervous system metastases and\u002For carcinomatous meningitis;\n* Have undergone surgery before starting the study or have not recovered adequately from toxicity or complications caused by the intervention;\n* Have had allogeneic tissue\u002Fsolid organ transplantation;\n* Have severe hypersensitivity reactions (≥ grade 3) to PD-1 inhibitors and chemotherapy or any of its adjuvants, radiotherapy;\n* Have active autoimmune disease and require systemic treatment in the past 2 years;\n* Have a history of (non-infectious) pneumonia requiring steroid treatment;\n* Have a history of human immunodeficiency virus (HIV) infection;\n* Any medical history, treatment, or laboratory abnormality that could confound the study results, interfere with the participant's participation throughout the study, or be detrimental to the participant's best interests;\n* A known history of psychiatric or substance abuse disorder",{"count":514,"type":22},260,[144],"A prospective, multicenter, randomized controlled phase II study; Patients who met the inclusion criteria were divided into groups according to whether they had received radical radiotherapy or postoperative radiotherapy in the past. Group A was the group that had not received radiotherapy in the past, and Group B was the group that had received radiotherapy. Group A was randomly given 3 cycles of pembrolizumab + chemotherapy (see P22 for detailed chemotherapy regimen) in the experimental group at a 1:1 ratio, followed by surgery. After surgery, the patients were stratified according to whether there were high-risk factors. The high-risk group received concurrent chemoradiotherapy + pembrolizumab maintenance therapy (up to 15 cycles), and the low-risk group received radiotherapy + pembrolizumab maintenance therapy (up to 15 cycles). The control group underwent direct surgery and received concurrent chemoradiotherapy or radiotherapy after surgery. The total dose of radiotherapy was (high-risk group: 60-66Gy, 2Gy\u002Ftime; low-risk group: 44-50 Gy, 2Gy\u002Ftime) adjuvant therapy, and the radiotherapy time was within 2 months after surgery. Group B was randomly given 3 cycles of pembrolizumab + chemotherapy in the experimental group at a ratio of 1:1, followed by surgery and maintenance therapy with pembrolizumab after surgery (up to 15 cycles). The control group was given surgery directly, and observation\u002Fre-radiotherapy or chemoradiotherapy was chosen by the doctor after surgery. The total dose of radiotherapy was (56-60Gy, 2Gy\u002Ftime), and the radiotherapy time was within 2 months after surgery. The enrolled patients must be closely monitored for adverse reactions to chemotherapy, and the time, grade, treatment measures, and outcomes must be recorded. All patients received an examination after the end of neoadjuvant therapy, an examination after surgery, and an examination at the 9th week after the first radiotherapy, and then reviewed every 3 months for 1 year; after 1 year, they were reviewed once every 6 months for 3 years; the recurrence and survival data of the patients were recorded.",[518],"Head and Neck Cancer","2025-01-24",{"date":521,"type":36},"2025-01-27",{"date":503,"type":22},{"date":78,"type":22},{"name":42,"class":43},{"id":526,"slug":527,"hasResults":12,"nctId":528,"briefTitle":529,"officialTitle":530,"acronym":4,"eligibilityCriteria":531,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":532,"targetDuration":4,"studyType":23,"phases":534,"briefSummary":535,"conditions":536,"keywords":538,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":548,"locationsCount":80},"100572388","laser-acupuncture-for-idiopathic-bells-palsy-100572388","NCT06732622","Laser Acupuncture for Idiopathic Bell's Palsy","Laser Acupuncture for Idiopathic Bell's Palsy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 1\\. Patients diagnosed with idiopathic Bell's Palsy 2.Patients were eligible if they were graded at House-Brackmann grade (HB) 3 or higher.\n\nExclusion Criteria:\n\n* 1\\. Serious mental illness or social problems, and neurological disorders, and systemic diseases, such as malignant tumors, and other serious consumptive diseases. 2. Planning for pregnancy, those in pregnancy, or those who were lactating. 3.Bell's Palsy patients who have a disease course of more than 8 weeks.",{"count":533,"type":22},360,[56],"Bell's palsy is characterized by acute, unilateral onset that compromises function and esthetics, exerting a considerable impact on the social, professional, and psychological aspects of the lives of affected individuals. The objective of this study was to determine whether laser acupuncture therapy could relieve symptoms in patients with Bell's palsy.",[537],"Bell Palsy",[539,540,541,456],"Bell's Palsy","Laser acupuncture","Photobiomodulation","2024-12-10",{"date":544,"type":36},"2024-12-13",{"date":546,"type":36},"2024-12-01",{"date":75,"type":22},{"name":42,"class":43},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":4,"eligibilityCriteria":555,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":556,"targetDuration":4,"studyType":23,"phases":557,"briefSummary":558,"conditions":559,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":80},"100571841","phase-2-intra-arterial-chemotherapy-combined-with-radiotherapy-and-immunotherapy-for-hnscc-100571841","NCT06725498","Intra-arterial Chemotherapy Combined with Radiotherapy and Immunotherapy for HNSCC","A Prospective, Single-center, Open-label Phase II Clinical Study of Intra-arterial Chemotherapy Combined with Concurrent Radiotherapy and Tislelizumab-jsgr in the Treatment of T4bNanyM0 HNSCC","Inclusion Criteria:\n\n* Patients with T4bNanyM0 Head and neck squamous cell carcinoma (hypopharyngeal cancer, laryngeal cancer, oropharyngeal cancer or oral cavity) with a confirmed diagnosis by histology and\u002For cytology;\n* Expected survival ≥3 months, with adequate organ function;\n* Investigators believe they can safely receive treatment with PD-1 combined with platinum and albumin-bound paclitaxel;\n* Age ≥18 years;\n* ECOG score of 0-1;\n* Measurable disease as defined by RECIST v1.1;\n* Adequate bone marrow reserve and organ function: Absolute neutrophil count (ANC) ≥1,000\u002Fmicroliter (mcL), platelets ≥75,000\u002FmcL, hemoglobin ≥8g\u002FdL, without transfusion or dependence on erythropoietin (EPO) (within 7 days after assessment);\n* Renal function: Serum creatinine ≤1.5 times the upper limit of normal (ULN) OR measured or calculated creatinine clearance ≥60mL\u002Fmin with creatinine levels \\> 1.5 times the institutional ULN. (GFR can also be used in place of creatinine or CrCl). Creatinine clearance should be calculated according to institutional standards;\n* Liver function: For subjects with a total bilirubin level \\>1.5 ULN, serum total bilirubin ≤1.5 times ULN or direct bilirubin ≤ULN; For patients with liver metastases, aspartate aminotransferase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤2.5 times ULN OR ≤5 times ULN; Albumin \\> 2.5 mg\u002FdL;\n* Coagulation function: International normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN, if the subject is receiving anticoagulant therapy, PT or PTT should be within the permissible range of the anticoagulant used;\n* Females should agree to use contraceptive measures (such as intrauterine device (IUD), oral contraceptives, or condoms) during the study and for 6 months after the study ends; Negative serum or urine pregnancy test within 7 days before study entry, and must be non-lactating patients; Males should agree to use contraceptive measures during the study and for 6 months after the study ends.\n\nExclusion Criteria:\n\n* Patients with a history of prior immunotherapy, radiotherapy, and treatment with EGFR monoclonal antibodies;\n* Patients with a history of other (including unknown primary) malignant tumors within the past 5 years;\n* Patients who are intolerant to radiotherapy post-surgery;\n* Patients known to be allergic to the study medication or its active ingredients, excipients;\n* Patients with any unstable systemic diseases, including but not limited to: severe infections, uncontrolled diabetes, unstable angina, cerebrovascular accidents or transient ischemic attacks, myocardial infarction, congestive heart failure, serious arrhythmias requiring medication, liver, kidney, or metabolic disorders;\n* Patients with potential immune deficiencies, chronic infections, including HIV, hepatitis, tuberculosis (TB), or autoimmune diseases;\n* Patients with potential hematological issues, including bleeding disorders, known prior gastrointestinal bleeding requiring intervention within the past 6 months, active pulmonary embolism or deep vein thrombosis (DVT) that is unstable on anticoagulation regimens;\n* A history or any evidence of active noninfectious pneumonia;\n* Known active central nervous system (CNS) metastases and\u002For leptomeningeal disease or carcinomatous meningitis. Subjects with previously treated brain metastases may participate if they are stable (no evidence of imaging progression for at least four weeks prior to the first trial treatment and any neurological symptoms have returned to baseline), with no new or enlarging evidence of brain metastases, and are not on steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability;\n* Concurrent use (or receipt) of medications within 7 days prior to Day 1 of Cycle 1 that may affect drug metabolism;\n* Pregnant or breastfeeding, or expecting to become pregnant or father a child during the anticipated trial period;\n* Any uncontrollable concomitant diseases, including but not limited to persistent or active infections, symptomatic congestive heart failure, unstable angina, arrhythmias;\n* Prolonged corrected QT (QTc) interval \\> 475 ms on screening EKG;\n* Ejection fraction \\\u003C40% on 2D echocardiogram (ECHO) at screening;\n* Any serious medical or psychiatric illness\u002Fcondition, including substance use disorders, that may interfere with or limit adherence to study requirements\u002Ftreatment in the investigator's judgment;\n* Active autoimmune disease requiring systemic treatment in the past 2 years (i.e., the use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapies (e.g., thyroid hormone, insulin, or physiologic corticosteroid replacement for adrenal or pituitary insufficiency, etc.) are not considered a form of systemic treatment.",{"count":335,"type":22},[144],"This study pioneers a novel approach by integrating a new auxiliary chemo-immunotherapy regimen, which is then followed by an evaluation of the potential for surgical resection. For those patients who remain non-resectable, a tailored treatment plan is proposed, consisting of arterial infusion chemotherapy in conjunction with radiotherapy, succeeded by a series of immune checkpoint inhibitors. The efficacy and safety of this integrated therapeutic strategy are meticulously assessed, with the goal of enhancing survival outcomes for patients with T4bNanyM0 HNSCC.",[560],"Head and Neck Squamous Cell Carcinoma","2024-12-08",{"date":542,"type":36},{"date":546,"type":22},{"date":565,"type":22},"2029-11-30",{"name":42,"class":43},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":218,"enrollmentInfo":574,"targetDuration":4,"studyType":23,"phases":576,"briefSummary":577,"conditions":578,"keywords":580,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":80},"100569621","transcutaneous-auricular-vagus-nerve-stimulation-in-dry-eye-100569621","NCT06696625","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye","Transcutaneous Auricular Vagus Nerve Stimulation in Dry Eye: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age \\>=18 and Age \\\u003C=65.\n2. complaint of DED symptoms for 6 months or longer at screening.\n3. ocular surface disease index (OSDI) score of 25 or higher.\n4. tear film breakup time (TFBUT) of 5 seconds or less.\n5. Schirmer I test without anesthesia of 5 mm or more at 5 minutes.\n6. tCFS score of 4 or higher.\n\nExclusion Criteria:\n\n1. History systemic autoimmune diseases and ocular\u002Fperiocular malignancy.\n2. Clinically relevant slitlamp findings or abnormal lid anatomy.\n3. Active ocular allergies and active infection.\n4. Pregnant or lactating women.",{"count":575,"type":22},256,[56],"Objective: To evaluate the effect of transcutaneous auricular vagus nerve stimulation (taVNS) for the patients with dry eye disease.\n\nMethods: The investigators enrolled 256 patients at Beijing Tongren Hospital. Patients completed questionnaires at baseline, 1 month, 3 months, and 6 months. OSDI score, TBUT, Schirmer I, CFS, SF36, DEQ5, and psychological status to evaluate the therapeutic effects. A difference of P \\\u003C 0.05 was considered statistically significant.",[579],"Dry Eye Disease",[581,30,456],"taVNS","2024-11-18",{"date":584,"type":36},"2024-11-20",{"date":586,"type":36},"2021-07-01",{"date":588,"type":22},"2025-12-01",{"name":42,"class":43},{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":594,"acronym":4,"eligibilityCriteria":595,"healthyVolunteers":12,"sex":17,"minAge":382,"maxAge":4,"enrollmentInfo":596,"targetDuration":4,"studyType":23,"phases":597,"briefSummary":598,"conditions":599,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":601,"startDateStruct":602,"completionDateStruct":603,"leadSponsor":605,"locationsCount":80},"100555299","phase-2-efficacy-and-safety-of-taitacept-in-treatment-of-refractory-or-recurrent-anti-nmdaranti-lgi1-encephalitis-100555299","NCT06510283","Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR\u002Fanti-LGI1 Encephalitis","Inclusion Criteria:\n\n1. Age ≥14 years old, male or female;\n2. Symptoms of autoimmune encephalitis (AE) ≤ 9 months prior to enrollment;\n3. Diagnosed as autoimmune encephalitis, diagnostic criteria as follows:\n\n   1. Rapid onset (\\\u003C3 months) of at least four of the following six major symptoms:\n\n      * Abnormal (mental) behavior or cognitive dysfunction\n      * Speech dysfunction (verbal urgency, hypospeech, mutism)\n      * Seizures\n      * Movement disorders, dyskinesias, or postural rigidity\u002Fabnormalities\n      * Decreased level of consciousness\n      * Autonomic dysfunction or central hypoventilation in the presence of one or more of the six major symptoms;\n   2. Positive anti-NMDAR (GluN1) IgG antibody detected in CSF or positive serum and\u002For cerebrospinal fluid LGI1 antibody; c．Reasonable exclusion of other etiologies and other well-defined encephalitis syndromes (e.g., Bickerstaff brainstem encephalitis, acute disseminated encephalomyelitis, Hashimoto encephalopathy, primary CNS vasculitis, Rasmussen encephalitis);\n4. Refractory AE: ineffective treatment with steroids and rituximab or other immunosuppressants, post-treatment mRS score≥2 (stable for at least 24 hours）;Recurrent AE: at least 2 months after 1st or 2nd line treatment, new symptoms or worsening of existing symptoms (mRS increase\\>1); 5）Doses of steroids and other immunosuppressants (e.g. azathioprine, mycophenolate mofetil, cyclophosphamide) should be stabilised for 4 weeks prior to enrolment; 6）Ability to obtain patient or proxy consent; 7）Women of childbearing potential should use effective contraception during treatment or avoid heterosexual intercourse for at least 3 months after the last dose of talitacicept;\n\nExclusion Criteria:\n\n1. History of other autoimmunity such as SLE, RA, SS. Patients with hyperthyroidism and hypothyroidism cannot be excluded;\n2. Abnormal laboratory indicators, including but not limited to the following indicators:\n\n   White blood cell count\\\u003C3×10\\^9 \u002FL Neutrophil count\\\u003C1.5×10\\^9 \u002FL Hemoglobin\\\u003C85g\u002FL Blood platelet count\\\u003C80×10\\^9 \u002FL Serum creatinine\\>1.5×ULN TBil(total bilirubin) \\>1.5×ULN ALT\\>3× ULN AST\\>3× ULN Alkaline phosphatase\\>2× ULN Creatine kinase\\>5× ULN\n3. Evidence of active infection such as shingles, HIV or active tuberculosis, etc.\n4. Currently have active hepatitis or have severe liver disease and a history of it.\n\n   * Patiens with abnormal Hepatitis B test as follows should be excluded: HbsAg positive; HbsAg negative but HbcAb positive, and HBV-DNA positive. Whereas patients with HbsAg negative but HbcAb positive, and HBV-DNA negative can be included.\n   * Exclude patients who are positive for hepatitis C antibodies ;\n5. Uncontrolled diabetes mellitus: Glycosylated hemoglobin\\>9.0% or fasting blood glucose≥11.1mmol\u002FL;\n6. Received any live vaccine within 3 months prior to enrollment or planned to receive any vaccine during the study;\n7. Received rituximab or other biological therapies within 1 month prior to enrollment;\n8. Malignancy;\n9. Allergic to human biological products;\n10. Participated in any clinical trial within 28 days prior to enrollment or within 5 times the half-life of the investigational drug participating in the clinical trial\n11. Patients who plan to have children during the trial, or who are pregnant or breastfeeding;\n12. Alcohol or drug abuse\u002Faddiction is known to have an impact on compliance with trial requirements;\n13. Patients who are deemed unsuitable for the trial by the investigator (e.g., those with severe mental disorders).",{"count":120,"type":22},[144],"The main objective is to explore the efficacy and safety of Telitacicept in the treatment of refractory\u002Frecurrent anti-NMDAR and anti-LGI1 encephalitis.\n\nThrough this prospective, single-center, open-label clinical trial, we aim to investigate the effectiveness and safety of Telitacicept in refractory\u002Frecurrent anti-NMDAR and anti-LGI1 encephalitis by add-on therapy of Telitacicept combined with traditional treatment.",[600],"Anti-N-Methyl-D-Aspartate Receptor Encephalitis",{"date":584,"type":36},{"date":546,"type":22},{"date":604,"type":22},"2028-07-01",{"name":42,"class":43},""]